Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment

Article Abstract:

Women who experience premenstrual dysphoric disorder (PMDD) and stop taking fluoxetine may have a recurrence of symptoms, according to two studies of 517 women. This supports the idea that PMDD is a different disorder than depression. PMDD is a more severe form of premenstrual syndrome (PMS). Fluoxetine is the generic name for Prozac, which is called Serafem when it is used to treat PMS and PMDD.

Author: Pearlstein, Teri, Joliat, Melissa J., Brown, Eileen B., Miner, Cherri M.
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2003

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Fluoxetine (Sarafem) for premenstrual dysphoric disorder

Article Abstract:

The antidepressant drug Prozac is now marketed under the name Sarafem for the treatment of premenstrual syndrome. The drug may be effective when taken only for the two weeks before menstruation begins. Other effective drug treatments for premenstrual syndrome include Paxil, Zoloft, Effexor, Anafranil, and Celexa.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2001

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder

Article Abstract:

The luteal phase dosing with paroxetine controlled release (CR) is evaluated in the treatment of premenstrual dysphoric disorder (PMDD). Luteal phase dosing with 12.5 mg and 25 mg of paroxetine CR is found to be effective and well tolerated for the treatment of PMDD.

Author: Steiner, Meir, Hirschberg, Angelica Linden, Bergeron, Richard, Holland, Fiona, Gee, Michelle D., Erp, Elisabeth Van
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2005
United States, Dosage and administration, Paroxetine, Luteal phase defects

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Product/Service Evaluation, Drug therapy, Fluoxetine, Premenstrual syndrome, Sarafem (Medication)
Similar abstracts:
  • Abstracts: The use of fine-needle aspiration in the evaluation of persistent palpable dominant breast masses. Lack of utility in clinical practice of cytologic examination of nonbloody cyst fluid from palpable breast cysts
  • Abstracts: Incentives lower costs of e-prescribing. Doctors also ship work overseas (but they donEt always know it). Lurking ... listening ... learning
  • Abstracts: 20 years of restoring sight merits a big-top celebration. Framing history. How close should you be to your patients?
  • Abstracts: A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation
  • Abstracts: Sacrospinous cervicocolpopexy with uterine conservation for uterovaginal prolapse in elderly women: an evolving concept
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.